- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03373474
Warm Acupuncture for Breast Cancer Related Lymphedema
Comparison of Effectiveness Between Warm Acupuncture With Local-Distal Points Association and Local Distribution Points Association in Breast Cancer Related Lymphedema Patients: A Multicenter, Randomized, Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China
- Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 6 months after breast cancer surgery and presents with persistent breast cancer related upper extremity lymphedema for at least 3 months. Upper extremity lymphedema is defined as more than 2cm circumference difference or 5% volume difference between the affected and unaffected arms.
- Stage II or III lymphedema according to the 2016 consensus by the international society of lymphology.
- Karnofsky Performance Score (KPS) ≥ 70
- Men or women aged 18 to 80 years
- Out-patients
- Estimated life expectancy > 6 months
Exclusion Criteria:
- Bilateral breast cancer related lymphedema
- Taking diuretic
- History of primary lymphedema
- A diagnosis of severe heart, liver, kidney or hematologic disease
- Edema caused by upper extremity disability or other conditions such as heart failure, kidney disease or malnutrition
- Have hypoproteinemia
- Inflammation, scar, or trauma at the site of operation, or other active skin infections
- Unable to self-care, had a history of psychological disorders, or unable to communicate
- Received lymphedema treatment within the past 1 month
- Pregnancy or breastfeeding
- The presence of electronic medical device implants
- Deny to sign the informed written consent, or unwilling to conform to randomization
- Participation in other clinical trials during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: local distribution points association
Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
|
Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted. Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm. |
EXPERIMENTAL: local-distal points association
Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
|
Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm. Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9. |
NO_INTERVENTION: waiting-list
Patients in the waiting-list group will not receive any acupuncture treatment during the study.
However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper extremity circumference
Time Frame: 80 weeks
|
Various assessment methods are available but circumference measure is simple, convenient with low cost, and reliable.
Therefore, the primary outcome measures will be the mean change in inter-limb circumference difference from baseline to the end of the 8-week intervention.
The circumference will be measured by the measurement tape (Gulick Attachment, Baseline, America) at the wrist crease, 10 cm above the wrist crease, elbow crease, 10 cm above the elbow crease, where the lymphedema is most severe and its corresponding location on the unaffected limb.
|
80 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper extremity volume
Time Frame: 80 weeks
|
Volume measurement is also commonly used for the evaluation of lymphedema and the mean change in inter-limb volume difference from baseline to the end of the 8-week intervention will be included as the second primary outcome measure.
The volume of the affected and unaffected limb will be measured by the volumetric measuring device (Baseline, America) using the water displacement method, which is considered as the most reliable method for volume measurements.
|
80 weeks
|
Common terminology criteria for adverse events (CTCAE 4.03) - edema limbs criteria
Time Frame: 80 weeks
|
Common terminology criteria for adverse events (CTCAE 4.03) will be used to grade the severity of swelling using the edema limbs criteria.
A grading of mild, moderate or severe swelling will be assessed based on the inter-limb circumference or volume discrepancy, anatomic architecture, appearance, or activities of daily living.
The CTCAE 4.03 will allow us to evaluate the clinical significance of circumference change.
|
80 weeks
|
Stages of lymphedema from the international society of lymphology
Time Frame: 80 weeks
|
Stages of lymphedema from the international society of lymphology will be used to grade the severity of lymphedema.
Staging of 0, I, II, or III will be assessed based on severity of swelling, ability to reduce swelling by elevation, and skin changes.
|
80 weeks
|
The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure
Time Frame: 80 weeks
|
Disabilities of the arm, shoulder, and hand (DASH) is a scale consists of two concepts: functional status (part A) and symptoms (part B) respectively.
The functional status part is further divided into three dimensions: physical, social, and psychological.
The total score of the DASH ranges from 0 to 100 with higher scores representing worse symptoms and function.
The DASH has good validity and responsiveness and it is recommended to assess upper extremity function in breast cancer survivors.
The validated Chinese version of the DASH will be used in this study.
|
80 weeks
|
The MOS 36-Item Short-Form Health Survey (SF-36)
Time Frame: 80 weeks
|
The medical outcome study 36-item short-form health survey (SF-36) is a commonly used instrument to assess quality of life that has good validity.
The SF-36 includes the following eight concepts: physical functioning, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perception.
The validated Chinese version of the SF-36 will be used in this study.
|
80 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: XingFang Pan, Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014CB543202-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Lymphedema
-
Odense University HospitalZealand University Hospital; Vejle Hospital; Herlev and Gentofte HospitalRecruitingLymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema Arm | Lymphedema; SurgicalDenmark
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema, Breast Cancer | Lymphedema ArmUnited States
-
Hacettepe UniversityCompletedLymphedema, Breast CancerTurkey
-
Odense University HospitalDanish Cancer SocietyActive, not recruitingPathologic Processes | Neoplasms | Skin Diseases | Lymphatic Diseases | Postoperative Complications | Breast Cancer | Breast Diseases | Lymphedema | Breast Neoplasm | Surgery | Secondary Lymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema Arm | Iatrogenic Lymphedema | A... and other conditionsDenmark
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema of Upper Arm | Lymphedema, Breast CancerUnited States
-
Instituto Nacional de Cancer, BrazilRecruitingBreast Neoplasms | Lymphedema of Upper Arm | Breast Cancer Related Lymphedema | Lymphedema, SecondaryBrazil
-
Instituto Nacional de Cancer, BrazilCompletedBreast Neoplasms | Lymphedema of Upper Arm | Breast Cancer Related Lymphedema | Lymphedema, SecondaryBrazil
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Krebsforschung Schweiz, Bern, Switzerland; Rising Tide FoundationRecruitingLymphedema, Breast CancerSpain, Switzerland, United States, Germany, Argentina, Austria, Belgium, Brazil, Canada, Greece, Italy, Netherlands, Romania, Sweden
-
Massachusetts General HospitalHeinz Family FoundationRecruitingBreast Cancer | Lymphedema | Edema | Lymphedema of Upper Arm | Breast Cancer Lymphedema | Breast Cancer Metastatic | Lymphedema of Upper Limb | Breast Cancer Stage | Lymphedema Arm | Edema Arm | Lymphedema of the HandsUnited States
-
Izmir Bakircay UniversityBezmialem Vakif University; Istanbul Kent UniversityCompletedLymphedema, Breast Cancer | Lymphedema of Upper LimbTurkey
Clinical Trials on local distribution points association
-
Hacettepe UniversityCompletedChronic Venous Insufficiency | LipedemaTurkey
-
Rabin Medical CenterEu Fifth Framework ISTCompletedCross Infection | Community-Acquired InfectionGermany, Israel, Italy
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
University of Sao PauloCompletedCancer | Myofascial Pain SyndromesBrazil
-
Sonderborg HospitalAase and Ejnar Danielsens Foundation; The Augustinus Foundation, Denmark.; The...CompletedPain | Lacerations | Birth InjuriesDenmark
-
Gia Dinh People HospitalCompletedLiver Diseases | Adult DiseaseVietnam
-
University of Lausanne HospitalsCompleted
-
UMC UtrechtNational University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaboratorsRecruitingCommunity-acquired Pneumonia, Influenza, COVID-19United Kingdom, United States, Canada, Australia, Netherlands, Croatia, Germany, Belgium, New Zealand, Ireland, Spain, Japan, Hungary, Colombia, India, Nepal, Pakistan, Portugal, Romania, Saudi Arabia